APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oligonucleotides

Oligonucleotides are short nucleic acid polymers used in research, genetic testing and forensics.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Oligonucleotides are short nucleic acid polymers used in research, genetic testing and forensics.

Oligonucleotides are usually made up of 13 to 25 nucleotides and are designed to hybridize specifically to DNA or RNA sequences. Solid-phase clinical synthesis is used to manufacture these small bits of nucleic acid for use in polymerase chain reaction (PCR), DNA sequencing, library construction and artificial gene synthesis.

Selected research

Market Analysis & Forecast

Global Oligonucleotides Market Analysis and Forecast 2026-2032

20 December 2025208 pages

Choose your research edition.

Industry ResearchOligonucleotides Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Oligonucleotides Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Oligonucleotides Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oligonucleotides Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Oligonucleotides Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

Oligonucleotides are short nucleic acid polymers used in research, genetic testing and forensics.

Oligonucleotides are usually made up of 13 to 25 nucleotides and are designed to hybridize specifically to DNA or RNA sequences. Solid-phase clinical synthesis is used to manufacture these small bits of nucleic acid for use in polymerase chain reaction (PCR), DNA sequencing, library construction and artificial gene synthesis.

Global Oligonucleotides key players include Integrated DNA Technologies, Agilent, Sigma-aldrich, Eurofins Genomics, L.G.C Biosearch Technologies, etc. Global top five manufacturers hold a share over 45%.

Read the full market overview

North America is the largest market, with a share over 35%, followed by Europe and China, both have a share over 35percent.

In terms of product, DNA Oligos is the largest segment, with a share over 65%. And in terms of application, the largest application is Research, followed by Pharmaceutical.

Report Includes

This report presents an overview of global market for Oligonucleotides, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Oligonucleotides, also provides the revenue of main regions and countries. Of the upcoming market potential for Oligonucleotides, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oligonucleotides revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Oligonucleotides market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Oligonucleotides revenue, projected growth trends, production technology, application and end-user industry.

Oligonucleotides Segment by Company

Integrated DNA Technologies

Agilent

Sigma-aldrich

Eurofins Genomics

L.G.C Biosearch Technologies

Eurogentec S.A

Nitto Denko Avecia Inc

GenScript

BBI Life Sciences

GeneDesign

TriLink BioTechnologies

SGS DNA

LC Sciences

Twist Bioscience

Creative Biogene

General Biosystems

Oligonucleotides Segment by Type

DNA Oligos

RNA Oligos

Oligonucleotides Segment by Application

Pharmaceutical

Research

Diagnostic

Oligonucleotides Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotides market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oligonucleotides and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotides.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Oligonucleotides in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Oligonucleotides company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oligonucleotides revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oligonucleotides Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. DNA Oligos Major Player Table 3. RNA Oligos Major Player Table 4. Global Oligonucleotides Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Pharmaceutical Major Player Table 6. Research Major Player Table 7. Diagnostic Major Player Table 8. Oligonucleotides Industry Trends Table 9. Oligonucleotides Industry Drivers Table 10. Oligonucleotides Industry Opportunities and Challenges Table 11. Oligonucleotides Industry Restraints Table 12. Global Oligonucleotides Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Oligonucleotides Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Oligonucleotides Market Share by Region (2021-2026) Table 15. Global Oligonucleotides Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Oligonucleotides Market Share by Region (2027-2032) Table 17. Global Oligonucleotides Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Oligonucleotides Revenue Market Share by Players (2021-2026) Table 19. Global Oligonucleotides Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Oligonucleotides Key Players Headquarters & Area Served Table 21. Global Oligonucleotides Players, Product Type & Application Table 22. Global Oligonucleotides Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Oligonucleotides by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Oligonucleotides Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Oligonucleotides Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Oligonucleotides Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Oligonucleotides Revenue Market Share by Type (2021-2026) Table 29. Global Oligonucleotides Revenue Market Share by Type (2027-2032) Table 30. Global Oligonucleotides Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Oligonucleotides Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Oligonucleotides Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Oligonucleotides Revenue Market Share by Application (2021-2026) Table 34. Global Oligonucleotides Revenue Market Share by Application (2027-2032) Table 35. Integrated DNA Technologies Company Information Table 36. Integrated DNA Technologies Business Overview Table 37. Integrated DNA Technologies Oligonucleotides Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Integrated DNA Technologies Oligonucleotides Product Portfolio Table 39. Integrated DNA Technologies Recent Development Table 40. Agilent Company Information Table 41. Agilent Business Overview Table 42. Agilent Oligonucleotides Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Agilent Oligonucleotides Product Portfolio Table 44. Agilent Recent Development Table 45. Sigma-aldrich Company Information Table 46. Sigma-aldrich Business Overview Table 47. Sigma-aldrich Oligonucleotides Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Sigma-aldrich Oligonucleotides Product Portfolio Table 49. Sigma-aldrich Recent Development Table 50. Eurofins Genomics Company Information Table 51. Eurofins Genomics Business Overview Table 52. Eurofins Genomics Oligonucleotides Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Eurofins Genomics Oligonucleotides Product Portfolio Table 54. Eurofins Genomics Recent Development Table 55. L.G.C Biosearch Technologies Company Information Table 56. L.G.C Biosearch Technologies Business Overview Table 57. L.G.C Biosearch Technologies Oligonucleotides Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. L.G.C Biosearch Technologies Oligonucleotides Product Portfolio Table 59. L.G.C Biosearch Technologies Recent Development Table 60. Eurogentec S.A Company Information Table 61. Eurogentec S.A Business Overview Table 62. Eurogentec S.A Oligonucleotides Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Eurogentec S.A Oligonucleotides Product Portfolio Table 64. Eurogentec S.A Recent Development Table 65. Nitto Denko Avecia Inc Company Information Table 66. Nitto Denko Avecia Inc Business Overview Table 67. Nitto Denko Avecia Inc Oligonucleotides Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Nitto Denko Avecia Inc Oligonucleotides Product Portfolio Table 69. Nitto Denko Avecia Inc Recent Development Table 70. GenScript Company Information Table 71. GenScript Business Overview Table 72. GenScript Oligonucleotides Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. GenScript Oligonucleotides Product Portfolio Table 74. GenScript Recent Development Table 75. BBI Life Sciences Company Information Table 76. BBI Life Sciences Business Overview Table 77. BBI Life Sciences Oligonucleotides Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. BBI Life Sciences Oligonucleotides Product Portfolio Table 79. BBI Life Sciences Recent Development Table 80. GeneDesign Company Information Table 81. GeneDesign Business Overview Table 82. GeneDesign Oligonucleotides Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. GeneDesign Oligonucleotides Product Portfolio Table 84. GeneDesign Recent Development Table 85. TriLink BioTechnologies Company Information Table 86. TriLink BioTechnologies Business Overview Table 87. TriLink BioTechnologies Oligonucleotides Sales (Million MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 88. TriLink BioTechnologies Oligonucleotides Product Portfolio Table 89. TriLink BioTechnologies Recent Development Table 90. SGS DNA Company Information Table 91. SGS DNA Business Overview Table 92. SGS DNA Oligonucleotides Sales (Million MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 93. SGS DNA Oligonucleotides Product Portfolio Table 94. SGS DNA Recent Development Table 95. LC Sciences Company Information Table 96. LC Sciences Business Overview Table 97. LC Sciences Oligonucleotides Sales (Million MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 98. LC Sciences Oligonucleotides Product Portfolio Table 99. LC Sciences Recent Development Table 100. Twist Bioscience Company Information Table 101. Twist Bioscience Business Overview Table 102. Twist Bioscience Oligonucleotides Sales (Million MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 103. Twist Bioscience Oligonucleotides Product Portfolio Table 104. Twist Bioscience Recent Development Table 105. Creative Biogene Company Information Table 106. Creative Biogene Business Overview Table 107. Creative Biogene Oligonucleotides Sales (Million MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 108. Creative Biogene Oligonucleotides Product Portfolio Table 109. Creative Biogene Recent Development Table 110. General Biosystems Company Information Table 111. General Biosystems Business Overview Table 112. General Biosystems Oligonucleotides Sales (Million MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 113. General Biosystems Oligonucleotides Product Portfolio Table 114. General Biosystems Recent Development Table 115. North America Oligonucleotides Revenue by Type (2021-2026) & (US$ Million) Table 116. North America Oligonucleotides Revenue by Type (2027-2032) & (US$ Million) Table 117. North America Oligonucleotides Revenue by Application (2021-2026) & (US$ Million) Table 118. North America Oligonucleotides Revenue by Application (2027-2032) & (US$ Million) Table 119. North America Oligonucleotides Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. North America Oligonucleotides Revenue by Country (2021-2026) & (US$ Million) Table 121. North America Oligonucleotides Revenue by Country (US$ Million) & (2027-2032) Table 122. Europe Oligonucleotides Revenue by Type (2021-2026) & (US$ Million) Table 123. Europe Oligonucleotides Revenue by Type (2027-2032) & (US$ Million) Table 124. Europe Oligonucleotides Revenue by Application (2021-2026) & (US$ Million) Table 125. Europe Oligonucleotides Revenue by Application (2027-2032) & (US$ Million) Table 126. Europe Oligonucleotides Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. Europe Oligonucleotides Revenue by Country (2021-2026) & (US$ Million) Table 128. Europe Oligonucleotides Revenue by Country (US$ Million) & (2027-2032) Table 129. China Oligonucleotides Revenue by Type (2021-2026) & (US$ Million) Table 130. China Oligonucleotides Revenue by Type (2027-2032) & (US$ Million) Table 131. China Oligonucleotides Revenue by Application (2021-2026) & (US$ Million) Table 132. China Oligonucleotides Revenue by Application (2027-2032) & (US$ Million) Table 133. Asia Oligonucleotides Revenue by Type (2021-2026) & (US$ Million) Table 134. Asia Oligonucleotides Revenue by Type (2027-2032) & (US$ Million) Table 135. Asia Oligonucleotides Revenue by Application (2021-2026) & (US$ Million) Table 136. Asia Oligonucleotides Revenue by Application (2027-2032) & (US$ Million) Table 137. Asia Oligonucleotides Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 138. Asia Oligonucleotides Revenue by Region (US$ Million) & (2021-2026) Table 139. Asia Oligonucleotides Revenue by Region (US$ Million) & (2027-2032) Table 140. SAMEA Oligonucleotides Revenue by Type (2021-2026) & (US$ Million) Table 141. SAMEA Oligonucleotides Revenue by Type (2027-2032) & (US$ Million) Table 142. SAMEA Oligonucleotides Revenue by Application (2021-2026) & (US$ Million) Table 143. SAMEA Oligonucleotides Revenue by Application (2027-2032) & (US$ Million) Table 144. SAMEA Oligonucleotides Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 145. SAMEA Oligonucleotides Revenue by Country (2021-2026) & (US$ Million) Table 146. SAMEA Oligonucleotides Revenue by Country (US$ Million) & (2027-2032) Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Oligonucleotides Image Figure 2. Global Oligonucleotides Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oligonucleotides Market Size Share 2021 VS 2025 VS 2032 Figure 4. DNA Oligos Image Figure 5. RNA Oligos Image Figure 6. Global Oligonucleotides Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Oligonucleotides Market Size Share 2021 VS 2025 VS 2032 Figure 8. Pharmaceutical Image Figure 9. Research Image Figure 10. Diagnostic Image Figure 11. Global Oligonucleotides Market Size (US$ Million) & (2021-2032) Figure 12. Global Oligonucleotides Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Oligonucleotides Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Oligonucleotides Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Oligonucleotides Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Oligonucleotides Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Oligonucleotides Revenue Market Share by Type (2021-2032) Figure 19. Global Oligonucleotides Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Oligonucleotides Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Oligonucleotides Revenue Market Share by Application (2021-2032) Figure 22. North America Oligonucleotides Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Oligonucleotides Revenue Share by Type (2021-2032) Figure 24. North America Oligonucleotides Revenue Share by Application (2021-2032) Figure 25. North America Oligonucleotides Revenue Share by Country (2021-2032) Figure 26. United States Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Oligonucleotides Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Oligonucleotides Revenue Share by Type (2021-2032) Figure 31. Europe Oligonucleotides Revenue Share by Application (2021-2032) Figure 32. Europe Oligonucleotides Revenue Share by Country (2021-2032) Figure 33. Germany Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Oligonucleotides Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Oligonucleotides Revenue Share by Type (2021-2032) Figure 43. China Oligonucleotides Revenue Share by Application (2021-2032) Figure 44. Asia Oligonucleotides Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Oligonucleotides Revenue Share by Type (2021-2032) Figure 46. Asia Oligonucleotides Revenue Share by Application (2021-2032) Figure 47. Asia Oligonucleotides Revenue Share by Region (2021-2032) Figure 48. Japan Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Oligonucleotides Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Oligonucleotides Revenue Share by Type (2021-2032) Figure 56. SAMEA Oligonucleotides Revenue Share by Application (2021-2032) Figure 57. SAMEA Oligonucleotides Revenue Share by Country (2021-2032) Figure 58. Brazil Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • DNA Oligos
  • RNA Oligos
Applications
  • Pharmaceutical
  • Research
  • Diagnostic
Companies covered
  • Integrated DNA Technologies
  • Agilent
  • Sigma-aldrich
  • Eurofins Genomics
  • L.G.C Biosearch Technologies
  • Eurogentec S.A
  • Nitto Denko Avecia Inc
  • GenScript
  • BBI Life Sciences
  • GeneDesign
  • TriLink BioTechnologies
  • SGS DNA
  • LC Sciences
  • Twist Bioscience
  • Creative Biogene
  • General Biosystems

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Oligonucleotides Market by Type
  3. 1.2.1 Global Oligonucleotides Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 DNA Oligos
  5. 1.2.3 RNA Oligos
  6. 1.3 Oligonucleotides Market by Application
  7. 1.3.1 Global Oligonucleotides Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Pharmaceutical
  9. 1.3.3 Research
  10. 1.3.4 Diagnostic
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Oligonucleotides Market Dynamics
  1. 2.1 Oligonucleotides Industry Trends
  2. 2.2 Oligonucleotides Industry Drivers
  3. 2.3 Oligonucleotides Industry Opportunities and Challenges
  4. 2.4 Oligonucleotides Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Oligonucleotides Market Perspective (2021-2032)
  2. 3.2 Global Oligonucleotides Growth Trends by Region
  3. 3.2.1 Global Oligonucleotides Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Oligonucleotides Market Size by Region (2021-2026)
  5. 3.2.3 Global Oligonucleotides Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Oligonucleotides Revenue by Players
  2. 4.1.1 Global Oligonucleotides Revenue by Players (2021-2026)
  3. 4.1.2 Global Oligonucleotides Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Oligonucleotides Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Oligonucleotides Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Oligonucleotides Key Players Headquarters & Area Served
  7. 4.4 Global Oligonucleotides Players, Product Type & Application
  8. 4.5 Global Oligonucleotides Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Oligonucleotides Market CR5 and HHI
  11. 4.6.3 2025 Oligonucleotides Tier 1, Tier 2, and Tier 3
5 Oligonucleotides Market Size by Type
  1. 5.1 Global Oligonucleotides Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Oligonucleotides Revenue by Type (2021-2032)
  3. 5.3 Global Oligonucleotides Revenue Market Share by Type (2021-2032)
6 Oligonucleotides Market Size by Application
  1. 6.1 Global Oligonucleotides Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Oligonucleotides Revenue by Application (2021-2032)
  3. 6.3 Global Oligonucleotides Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Integrated DNA Technologies
  2. 7.1.1 Integrated DNA Technologies Company Information
  3. 7.1.2 Integrated DNA Technologies Business Overview
  4. 7.1.3 Integrated DNA Technologies Oligonucleotides Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Integrated DNA Technologies Oligonucleotides Product Portfolio
  6. 7.1.5 Integrated DNA Technologies Recent Developments
  7. 7.2 Agilent
  8. 7.2.1 Agilent Company Information
  9. 7.2.2 Agilent Business Overview
  10. 7.2.3 Agilent Oligonucleotides Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Agilent Oligonucleotides Product Portfolio
  12. 7.2.5 Agilent Recent Developments
  13. 7.3 Sigma-aldrich
  14. 7.3.1 Sigma-aldrich Company Information
  15. 7.3.2 Sigma-aldrich Business Overview
  16. 7.3.3 Sigma-aldrich Oligonucleotides Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sigma-aldrich Oligonucleotides Product Portfolio
  18. 7.3.5 Sigma-aldrich Recent Developments
  19. 7.4 Eurofins Genomics
  20. 7.4.1 Eurofins Genomics Company Information
  21. 7.4.2 Eurofins Genomics Business Overview
  22. 7.4.3 Eurofins Genomics Oligonucleotides Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Eurofins Genomics Oligonucleotides Product Portfolio
  24. 7.4.5 Eurofins Genomics Recent Developments
  25. 7.5 L.G.C Biosearch Technologies
  26. 7.5.1 L.G.C Biosearch Technologies Company Information
  27. 7.5.2 L.G.C Biosearch Technologies Business Overview
  28. 7.5.3 L.G.C Biosearch Technologies Oligonucleotides Revenue and Gross Margin (2021-2026)
  29. 7.5.4 L.G.C Biosearch Technologies Oligonucleotides Product Portfolio
  30. 7.5.5 L.G.C Biosearch Technologies Recent Developments
  31. 7.6 Eurogentec S.A
  32. 7.6.1 Eurogentec S.A Company Information
  33. 7.6.2 Eurogentec S.A Business Overview
  34. 7.6.3 Eurogentec S.A Oligonucleotides Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Eurogentec S.A Oligonucleotides Product Portfolio
  36. 7.6.5 Eurogentec S.A Recent Developments
  37. 7.7 Nitto Denko Avecia Inc
  38. 7.7.1 Nitto Denko Avecia Inc Company Information
  39. 7.7.2 Nitto Denko Avecia Inc Business Overview
  40. 7.7.3 Nitto Denko Avecia Inc Oligonucleotides Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Nitto Denko Avecia Inc Oligonucleotides Product Portfolio
  42. 7.7.5 Nitto Denko Avecia Inc Recent Developments
  43. 7.8 GenScript
  44. 7.8.1 GenScript Company Information
  45. 7.8.2 GenScript Business Overview
  46. 7.8.3 GenScript Oligonucleotides Revenue and Gross Margin (2021-2026)
  47. 7.8.4 GenScript Oligonucleotides Product Portfolio
  48. 7.8.5 GenScript Recent Developments
  49. 7.9 BBI Life Sciences
  50. 7.9.1 BBI Life Sciences Company Information
  51. 7.9.2 BBI Life Sciences Business Overview
  52. 7.9.3 BBI Life Sciences Oligonucleotides Revenue and Gross Margin (2021-2026)
  53. 7.9.4 BBI Life Sciences Oligonucleotides Product Portfolio
  54. 7.9.5 BBI Life Sciences Recent Developments
  55. 7.10 GeneDesign
  56. 7.10.1 GeneDesign Company Information
  57. 7.10.2 GeneDesign Business Overview
  58. 7.10.3 GeneDesign Oligonucleotides Revenue and Gross Margin (2021-2026)
  59. 7.10.4 GeneDesign Oligonucleotides Product Portfolio
  60. 7.10.5 GeneDesign Recent Developments
  61. 7.11 TriLink BioTechnologies
  62. 7.11.1 TriLink BioTechnologies Company Information
  63. 7.11.2 TriLink BioTechnologies Business Overview
  64. 7.11.3 TriLink BioTechnologies Oligonucleotides Revenue and Gross Margin (2021-2026)
  65. 7.11.4 TriLink BioTechnologies Oligonucleotides Product Portfolio
  66. 7.11.5 TriLink BioTechnologies Recent Developments
  67. 7.12 SGS DNA
  68. 7.12.1 SGS DNA Company Information
  69. 7.12.2 SGS DNA Business Overview
  70. 7.12.3 SGS DNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  71. 7.12.4 SGS DNA Oligonucleotides Product Portfolio
  72. 7.12.5 SGS DNA Recent Developments
  73. 7.13 LC Sciences
  74. 7.13.1 LC Sciences Company Information
  75. 7.13.2 LC Sciences Business Overview
  76. 7.13.3 LC Sciences Oligonucleotides Revenue and Gross Margin (2021-2026)
  77. 7.13.4 LC Sciences Oligonucleotides Product Portfolio
  78. 7.13.5 LC Sciences Recent Developments
  79. 7.14 Twist Bioscience
  80. 7.14.1 Twist Bioscience Company Information
  81. 7.14.2 Twist Bioscience Business Overview
  82. 7.14.3 Twist Bioscience Oligonucleotides Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Twist Bioscience Oligonucleotides Product Portfolio
  84. 7.14.5 Twist Bioscience Recent Developments
  85. 7.15 Creative Biogene
  86. 7.15.1 Creative Biogene Company Information
  87. 7.15.2 Creative Biogene Business Overview
  88. 7.15.3 Creative Biogene Oligonucleotides Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Creative Biogene Oligonucleotides Product Portfolio
  90. 7.15.5 Creative Biogene Recent Developments
  91. 7.16 General Biosystems
  92. 7.16.1 General Biosystems Company Information
  93. 7.16.2 General Biosystems Business Overview
  94. 7.16.3 General Biosystems Oligonucleotides Revenue and Gross Margin (2021-2026)
  95. 7.16.4 General Biosystems Oligonucleotides Product Portfolio
  96. 7.16.5 General Biosystems Recent Developments
8 North America
  1. 8.1 North America Oligonucleotides Revenue (2021-2032)
  2. 8.2 North America Oligonucleotides Revenue by Type (2021-2032)
  3. 8.2.1 North America Oligonucleotides Revenue by Type (2021-2026)
  4. 8.2.2 North America Oligonucleotides Revenue by Type (2027-2032)
  5. 8.3 North America Oligonucleotides Revenue Share by Type (2021-2032)
  6. 8.4 North America Oligonucleotides Revenue by Application (2021-2032)
  7. 8.4.1 North America Oligonucleotides Revenue by Application (2021-2026)
  8. 8.4.2 North America Oligonucleotides Revenue by Application (2027-2032)
  9. 8.5 North America Oligonucleotides Revenue Share by Application (2021-2032)
  10. 8.6 North America Oligonucleotides Revenue by Country
  11. 8.6.1 North America Oligonucleotides Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Oligonucleotides Revenue by Country (2021-2026)
  13. 8.6.3 North America Oligonucleotides Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Oligonucleotides Revenue (2021-2032)
  2. 9.2 Europe Oligonucleotides Revenue by Type (2021-2032)
  3. 9.2.1 Europe Oligonucleotides Revenue by Type (2021-2026)
  4. 9.2.2 Europe Oligonucleotides Revenue by Type (2027-2032)
  5. 9.3 Europe Oligonucleotides Revenue Share by Type (2021-2032)
  6. 9.4 Europe Oligonucleotides Revenue by Application (2021-2032)
  7. 9.4.1 Europe Oligonucleotides Revenue by Application (2021-2026)
  8. 9.4.2 Europe Oligonucleotides Revenue by Application (2027-2032)
  9. 9.5 Europe Oligonucleotides Revenue Share by Application (2021-2032)
  10. 9.6 Europe Oligonucleotides Revenue by Country
  11. 9.6.1 Europe Oligonucleotides Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Oligonucleotides Revenue by Country (2021-2026)
  13. 9.6.3 Europe Oligonucleotides Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Oligonucleotides Revenue (2021-2032)
  2. 10.2 China Oligonucleotides Revenue by Type (2021-2032)
  3. 10.2.1 China Oligonucleotides Revenue by Type (2021-2026)
  4. 10.2.2 China Oligonucleotides Revenue by Type (2027-2032)
  5. 10.3 China Oligonucleotides Revenue Share by Type (2021-2032)
  6. 10.4 China Oligonucleotides Revenue by Application (2021-2032)
  7. 10.4.1 China Oligonucleotides Revenue by Application (2021-2026)
  8. 10.4.2 China Oligonucleotides Revenue by Application (2027-2032)
  9. 10.5 China Oligonucleotides Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Oligonucleotides Revenue (2021-2032)
  2. 11.2 Asia Oligonucleotides Revenue by Type (2021-2032)
  3. 11.2.1 Asia Oligonucleotides Revenue by Type (2021-2026)
  4. 11.2.2 Asia Oligonucleotides Revenue by Type (2027-2032)
  5. 11.3 Asia Oligonucleotides Revenue Share by Type (2021-2032)
  6. 11.4 Asia Oligonucleotides Revenue by Application (2021-2032)
  7. 11.4.1 Asia Oligonucleotides Revenue by Application (2021-2026)
  8. 11.4.2 Asia Oligonucleotides Revenue by Application (2027-2032)
  9. 11.5 Asia Oligonucleotides Revenue Share by Application (2021-2032)
  10. 11.6 Asia Oligonucleotides Revenue by Country
  11. 11.6.1 Asia Oligonucleotides Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Oligonucleotides Revenue by Country (2021-2026)
  13. 11.6.3 Asia Oligonucleotides Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Oligonucleotides Revenue (2021-2032)
  2. 12.2 SAMEA Oligonucleotides Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Oligonucleotides Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Oligonucleotides Revenue by Type (2027-2032)
  5. 12.3 SAMEA Oligonucleotides Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Oligonucleotides Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Oligonucleotides Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Oligonucleotides Revenue by Application (2027-2032)
  9. 12.5 SAMEA Oligonucleotides Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Oligonucleotides Revenue by Country
  11. 12.6.1 SAMEA Oligonucleotides Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Oligonucleotides Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Oligonucleotides Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst